Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GLM045
MIFTS: 55

Glioma

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Glioma

About this section

MalaCards integrated aliases for Glioma:

Name: Glioma 53 37 29 55 73

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

KEGG 37 H00042
UMLS 73 C0017638
Sources

Summaries for Glioma

About this section
NIH Rare Diseases : 53 Glioma refers to a type of brain tumor that develops from the glial cells, which are specialized cells that surround and support neurons (nerve cells) in the brain. It is generally classified based on which type of glial cell is involved in the tumor: Astocytoma - tumors that develop from star-shaped glial cells called astrocytes Ependymomas - tumors that arise from ependymal cells that line the ventricles of the brain and the center of the spinal cord Oligodendrogliomas - tumors that affect the oligodendrocytes The symptoms of glioma vary by type but may include headaches; nausea and vomiting; confusion; personality changes; trouble with balance; vision problems; speech difficulties; and/or seizures. The exact underlying cause is unknown. In most cases, the tumor occurs sporadically in people with no family history of the condition. Treatment depends on many factors, including the type, size, stage and location of the tumor, but may include surgery, radiation therapy, chemotherapy and/or targeted therapy.

MalaCards based summary : Glioma is related to malignant glioma and astrocytoma. An important gene associated with Glioma is MIR21 (MicroRNA 21), and among its related pathways/superpathways are Glioma and MicroRNAs in cancer. The drugs Gliadel Wafer and Dacarbazine have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and endothelial.

Wikipedia : 76 A glioma is a type of tumor that starts in the glial cells of the brain or the spine. Gliomas comprise... more...

Sources

Related Diseases for Glioma

About this section

Diseases in the Glioma family:

Malignant Glioma Benign Glioma

Diseases related to Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 464)
# Related Disease Score Top Affiliating Genes
1 malignant glioma 34.0 CDKN2B-AS1 HOTAIR PVT1
2 astrocytoma 32.7 H19 HOTAIR LINC00461 MIR21 TP73-AS1
3 retinoblastoma 32.4 HOTAIR MALAT1 MEG3 MIR34A
4 neuroblastoma 31.2 H19 HOTAIR MALAT1 MEG3 MIR184 MIR221
5 glioblastoma 31.0 H19 HOTAIR MALAT1 MEG3 MIR181A2 MIR21
6 medulloblastoma 30.6 CDKN2B-AS1 H19 HOTAIR MIR17 MIR34A
7 melanoma 30.6 CDKN2B-AS1 H19 HOTAIR MALAT1 MEG3 MIR181A2
8 pituitary adenoma 30.3 H19 HOTAIR MALAT1 MEG3
9 small cell cancer of the lung 30.3 HOTAIR MALAT1 MIR21
10 lung cancer 30.2 CDKN2B-AS1 H19 HOTAIR MALAT1 MEG3 MIR146B
11 squamous cell carcinoma 30.1 CDKN2B-AS1 H19 HOTAIR MALAT1 UCA1
12 b-cell lymphomas 30.0 HOTAIR MALAT1 MIR17 PVT1
13 osteogenic sarcoma 30.0 CDKN2B-AS1 H19 HOTAIR MALAT1 MEG3 PVT1
14 hepatocellular carcinoma 30.0 CDKN2B-AS1 H19 HOTAIR MALAT1 MEG3 MIR181A2
15 breast cancer 29.9 CDKN2B-AS1 FOXO1 H19 HOTAIR MALAT1 MEG3
16 diabetes mellitus 29.9 CDKN2B-AS1 MALAT1 MEG3 MIR181A2 MIR34A PVT1
17 lung cancer susceptibility 3 29.9 H19 HOTAIR MALAT1 MEG3
18 leukemia, acute myeloid 29.8 CDKN2B-AS1 HOTAIR MALAT1 MEG3 MIR15B MIR181A2
19 gastric cancer 29.8 CDKN2B-AS1 H19 HOTAIR MALAT1 MEG3 MIR15B
20 renal cell carcinoma, nonpapillary 29.8 H19 HOTAIR MALAT1 PVT1 UCA1
21 nasopharyngeal carcinoma 29.8 CDKN2B-AS1 H19 HOTAIR MALAT1 MEG3 PVT1
22 pancreatic cancer 29.7 CDKN2B-AS1 H19 HOTAIR MALAT1 MEG3 MIR15B
23 thyroid cancer, nonmedullary, 1 29.6 H19 HOTAIR MALAT1 MEG3 MIR146B MIR181A2
24 ovarian cancer 29.5 CDKN2B-AS1 H19 HOTAIR MALAT1 MEG3 MIR146B
25 prostate cancer 29.5 CDKN2B-AS1 FOXO1 H19 HOTAIR MALAT1 MEG3
26 glioma susceptibility 1 12.5
27 optic nerve glioma 12.5
28 diffuse intrinsic pontine glioma 12.4
29 brain stem glioma 12.4
30 glioma susceptibility 2 12.4
31 childhood brain stem glioma 12.4
32 optic pathway glioma 12.4
33 glioma susceptibility 3 12.3
34 glioma susceptibility 9 12.3
35 brain glioma 12.2
36 mixed glioma 12.2
37 third ventricle chordoid glioma 12.2
38 chordoid glioma 12.2
39 subependymal glioma 12.2
40 spinal cord glioma 12.1
41 childhood optic nerve glioma 12.1
42 angiocentric glioma 12.1
43 glioma susceptibility 4 12.0
44 glioma susceptibility 6 12.0
45 glioma susceptibility 8 12.0
46 adult brain stem glioma 12.0
47 adult brainstem mixed glioma 12.0
48 glioma susceptibility 5 12.0
49 glioma susceptibility 7 12.0
50 benign glioma 12.0

Graphical network of the top 20 diseases related to Glioma:



Diseases related to Glioma
Sources

Symptoms & Phenotypes for Glioma

About this section
Sources

Drugs & Therapeutics for Glioma

About this section

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Gliadel Wafer 18 49 CARMUSTINE Rhone-Poulenc Rorer, Guilford Pharmaceuticals February 1997

Drugs for Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 691)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
3
Mesna Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3375-50-6 598
4
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-22-7, 2068-78-2 5978
5
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-05-2, 1959-05-2 126941
6
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
7
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
8
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 41575-94-4 10339178 38904 498142
9
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
10
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
11
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
12
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
13
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99-66-1 3121
14 Piracetam Approved, Investigational Phase 4,Phase 2 7491-74-9
15
Midazolam Approved, Illicit Phase 4,Not Applicable 59467-70-8 4192
16 tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
17
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
18
Trametinib Approved Phase 4,Phase 1,Phase 2 871700-17-3 11707110
19
Dabrafenib Approved, Investigational Phase 4,Phase 2,Phase 1 1195765-45-7 44462760 44516822
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
21
Glutamic Acid Approved, Nutraceutical Phase 4,Not Applicable 56-86-0 33032
22 Etiracetam Investigational Phase 4,Phase 1,Phase 2,Not Applicable 33996-58-6
23
Lactitol Investigational Phase 4,Phase 2,Phase 1 585-86-4 3871
24 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
27 Nootropic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
28 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
34 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
35 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
36 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
47 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Folate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid Phase 4

Interventional clinical trials:

(show top 50) (show all 2178)
# Name Status NCT ID Phase Drugs
1 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Unknown status NCT02520635 Phase 4 supra-early TEMODAL® chemotherapy;standard TEMODAL® chemotherapy
2 Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
3 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4 Temozolomide
4 Seizure Treatment in Glioma Recruiting NCT03048084 Phase 4 Levetiracetam;Valproic Acid
5 Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy Recruiting NCT02193568 Phase 4
6 Dabrafenib and/or Trametinib Rollover Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
7 HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Recruiting NCT02875314 Phase 4 Induction;Single Cycle Intensive Chemotherapy;Tandem 3 Cycle Intensive Chemotherapy
8 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
9 Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4 Temozolomide
10 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
11 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Unknown status NCT02892708 Phase 3
12 Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia Unknown status NCT02363075 Phase 3 Dexamfetamine sulphate;placebo
13 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
14 Fluorescence-guided Surgery for Low- and High-grade Gliomas Unknown status NCT01502280 Phase 3 5-Aminolevulinic acid (ALA);Placebo - ascorbic acid
15 Cognitive Rehabilitation of Glioma Patients Unknown status NCT00256425 Phase 3
16 Prospective Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children Unknown status NCT01878266 Phase 3
17 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
18 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
19 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
20 3D Ultra Sound for Resection of Brain Tumors Unknown status NCT02150564 Phase 3
21 A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer Unknown status NCT02395016 Phase 3 nimotuzumab;Gemcitabine
22 Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
23 Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
24 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
25 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
26 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
27 The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients Unknown status NCT02623231 Phase 2, Phase 3 Escitalopram;placebo
28 Metronomic Temozolamide in Patients With Recurrent Glioblastoma Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
29 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
30 Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma Unknown status NCT00053872 Phase 3 cisplatin;lomustine;vincristine sulfate
31 Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT Completed NCT01460706 Phase 2, Phase 3 [68Ga]DOTATOC
32 Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
33 Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas Completed NCT01167322 Phase 3 NPC-07 for oral administration
34 Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children Completed NCT01635140 Phase 3
35 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid Completed NCT00241670 Phase 3 5-aminolevulinic acid (5-ALA)
36 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3 temozolomide
37 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
38 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
39 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
40 Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
41 High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
42 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
43 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
44 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
45 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
46 Radiation Therapy in Treating Patients With Brain Cancer Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
47 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
48 Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients Completed NCT00135876 Phase 3 dalteparin
49 Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
50 Chloroquine for Treatment of Glioblastoma Multiforme Completed NCT00224978 Phase 3 Chloroquine

Search NIH Clinical Center for Glioma

Sources

Genetic Tests for Glioma

About this section

Genetic tests related to Glioma:

# Genetic test Affiliating Genes
1 Glioma 29
Sources

Anatomical Context for Glioma

About this section

MalaCards organs/tissues related to Glioma:

41
Brain, T Cells, Endothelial, Spinal Cord, Testes, Bone, Lung
Sources

Publications for Glioma

About this section

Articles related to Glioma:

(show top 50) (show all 7368)
# Title Authors Year
1
Malignant optic glioma masked by suspected optic neuritis and central retinal vein occlusion. ( 30450148 )
2019
2
Diffuse Low-Grade Glioma-Related Epilepsy. ( 30470404 )
2019
3
Use of DNA-generated gold nanoparticles to radiosensitize and eradicate radioresistant glioma stem cells. ( 30499457 )
2019
4
Evaluation of Tumor Regulatory Genes and Apoptotic Pathways in The Cytotoxic Effect of Cytochalasin H on Malignant Human Glioma Cell Line (U87MG). ( 30507090 )
2019
5
Neferine inhibits proliferation, migration and invasion of U251 glioma cells by down-regulation of miR-10b. ( 30551353 )
2019
6
MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2. ( 30551476 )
2019
7
Delta-24-RGD Adenoviral Therapy Directs Oncolytic and Immune-Mediated Anti-Tumor Effects in Recurrent Malignant Glioma Patients. ( 30395338 )
2019
8
Low-Grade Glioma Radiotherapy Treatment and Trials. ( 30470398 )
2019
9
Molecular Pathogenesis of Low-Grade Glioma. ( 30470401 )
2019
10
Alterations in the Brain Microenvironment in Diffusely Infiltrating Low-Grade Glioma. ( 30470402 )
2019
11
Mapping in Low-Grade Glioma Surgery: Low- and High-Frequency Stimulation. ( 30470405 )
2019
12
Low-Grade Glioma: Epidemiology, Pathophysiology, Clinical Features, and Treatment. ( 30470410 )
2019
13
Lipid nanocapsules decorated and loaded with cannabidiol as targeted prolonged release carriers for glioma therapy: In vitro screening of critical parameters. ( 30472144 )
2019
14
Imaging Glioma Progression by Intravital Microscopy. ( 30315471 )
2019
15
Cell Cycle Dynamics in Glioma Cancer Stem Cells. ( 30324519 )
2019
16
Survival after radiation therapy for high-grade glioma. ( 30337846 )
2019
17
MicroRNA‑494 promotes the proliferation and migration of human glioma cancer cells through the protein kinase B/mechanistic target of rapamycin pathway by phosphatase and tensin homolog expression. ( 30365133 )
2019
18
Knockdown of PEBP4 inhibits human glioma cell growth and invasive potential via ERK1/2 signaling pathway. ( 30255656 )
2019
19
Wnt/β-catenin signaling cascade: A promising target for glioma therapy. ( 30277583 )
2019
20
Adaptive behavior impaired in children with low-grade glioma. ( 30152099 )
2019
21
Fsk and IBMX inhibit proliferation and proapoptotic of glioma stem cells via activation of cAMP signaling pathway. ( 30171713 )
2019
22
FOXO1 associated with sensitivity to chemotherapy drugs and glial-mesenchymal transition in glioma. ( 30216501 )
2019
23
Identification of key gene modules and pathways of human glioma through coexpression network. ( 30067869 )
2019
24
Use of metformin and survival of patients with high-grade glioma. ( 30091464 )
2019
25
Intraoperative Photodynamic Diagnosis Using Talaporfin Sodium Simultaneously Applied for Photodynamic Therapy against Malignant Glioma: A Prospective Clinical Study. ( 29441040 )
2018
26
Progressive optic nerve glioma: orbital biopsy technique using a surgical navigation system. ( 29426453 )
2018
27
Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma. ( 29666296 )
2018
28
Long non-coding RNA ENST01108 promotes carcinogenesis of glioma by acting as a molecular sponge to modulate miR-489. ( 29421578 )
2018
29
IDH1 mutation is associated with a higher preoperative seizure incidence in low-grade glioma: A systematic review and meta-analysis. ( 29414139 )
2018
30
Staged Image-guided Robotic Radiosurgery and Deferred Chemotherapy to Treat a Malignant Glioma During and After Pregnancy. ( 29632751 )
2018
31
Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment. ( 29571074 )
2018
32
Sinomenine Induces G1-Phase Cell Cycle Arrest and Apoptosis in Malignant Glioma Cells Via Downregulation of Sirtuin 1 and Induction of p53 Acetylation. ( 29756546 )
2018
33
Prevalence of human immunodeficiency virus infection in brain glioma patients: Is the virus protective from gliomas? ( 29930869 )
2018
34
Expression of Prostate-Specific Membrane Antigen (PSMA) in Brain Glioma and its Correlation with Tumor Grade. ( 29731795 )
2018
35
MicroRNA-124-3p represses cell growth and cell motility by targeting EphA2 in glioma. ( 29969628 )
2018
36
Hyperbaric oxygen inhibits production of CD3+ T cells in the thymus and facilitates malignant glioma cell growth. ( 29785863 )
2018
37
Prognostic significance of epidermal growth factor receptor expression in glioma patients. ( 29445288 )
2018
38
Expression and functional analysis of TCF4 isoforms in human glioma cells. ( 29436621 )
2018
39
The long non-coding RNA <i>HOTAIR</i> is transcriptionally activated by HOXA9 and is an independent prognostic marker in patients with malignant glioma. ( 29644006 )
2018
40
Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. ( 29746225 )
2018
41
CDK4/6 and PDGFRA Signaling as Therapeutic Targets in Diffuse Intrinsic Pontine Glioma. ( 29904623 )
2018
42
Corrigendum: Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma. ( 29897054 )
2018
43
Correction to: A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. ( 29063425 )
2018
44
End-of-Life Care in High-Grade Glioma Patients. The Palliative and Supportive Perspective. ( 29966347 )
2018
45
Isolated Optic Nerve Glioma in Children With and Without Neurofibromatosis: Retrospective Characterization and Analysis of Outcomes. ( 29502465 )
2018
46
Targeting the extradomain A of fibronectin allows identification of vascular resistance to antiangiogenic therapy in experimental glioma. ( 29963235 )
2018
47
ACE I/D sequence variants but not MTHFR C677T, is strongly linked to malignant glioma risk and its variant DD genotype may act as a promising predictive biomarker for overall survival of glioma patients. ( 29017962 )
2018
48
IL-13 receptors as possible therapeutic targets in diffuse intrinsic pontine glioma. ( 29621254 )
2018
49
Association Between IDH1 and IDH2 Mutations and Preoperative Seizures in Patients with Low-Grade Versus High-Grade Glioma: A Systematic Review and Meta-Analysis. ( 29288860 )
2018
50
Delineation of the visual pathway in paediatric optic pathway glioma patients using probabilistic tractography, and correlations with visual acuity. ( 29527480 )
2018
Sources

Variations for Glioma

About this section

Cosmic variations for Glioma:

9 (show top 50) (show all 6967)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM989 SMARCB1 central nervous system,brain,glioma,ependymoma Grade III-IV c.1130G>A p.R377H 22:23834152-23834152 9
2 COSM6289136 SMARCA4 central nervous system,brain,glioma,ependymoma Grade III-IV c.2143G>A p.D715N 19:11010400-11010400 9
3 COSM6958006 RB1 central nervous system,brain,glioma,ependymoma Grade III-IV c.380+2T>C p.? 13:48342716-48342716 9
4 COSM4749148 PTPRS central nervous system,brain,glioma,ependymoma Grade III-IV c.2600G>A p.R867H 19:5223192-5223192 9
5 COSM6968454 PIK3R3 central nervous system,brain,glioma,ependymoma Grade III-IV c.1320C>A p.H440Q 1:46043739-46043739 9
6 COSM6973319 PIK3C3 central nervous system,brain,glioma,ependymoma Grade III-IV c.929A>T p.Y310F 18:41996675-41996675 9
7 COSM6968460 KMT2C central nervous system,brain,glioma,ependymoma Grade III-IV c.14594G>A p.G4865E 7:152138845-152138845 9
8 COSM3662778 KMT2C central nervous system,brain,glioma,ependymoma Grade III-IV c.2491A>G p.T831A 7:152247943-152247943 9
9 COSM6968457 FLT4 central nervous system,brain,glioma,ependymoma Grade III-IV c.2105C>A p.A702D 5:180621168-180621168 9
10 COSM6942397 FH central nervous system,brain,glioma,ependymoma Grade III-IV c.258A>C p.E86D 1:241517191-241517191 9
11 COSM22965 FBXW7 central nervous system,brain,glioma,ependymoma Grade III-IV c.1394G>A p.R465H 4:152328232-152328232 9
12 COSM4607064 CDC73 central nervous system,brain,glioma,ependymoma Grade III-IV c.929A>G p.D310G 1:193152401-193152401 9
13 COSM1162555 APC central nervous system,brain,glioma,ependymoma Grade III-IV c.3007G>A p.D1003N 5:112838601-112838601 9
14 COSM1149856 central nervous system,brain,glioma,ependymoma Grade III-IV c.1040G>A p.R347H 4:152328232-152328232 9
15 COSM4749147 central nervous system,brain,glioma,ependymoma Grade III-IV c.2603G>A p.R868H 19:5223192-5223192 9
16 COSM117310 central nervous system,brain,glioma,ependymoma Grade III-IV c.1394G>A p.R465H 4:152328232-152328232 9
17 COSM6914403 central nervous system,brain,glioma,ependymoma Grade III-IV c.2588G>A p.R863H 19:5223192-5223192 9
18 COSM6968458 central nervous system,brain,glioma,ependymoma Grade III-IV c.1535C>A p.A512D 5:180621168-180621168 9
19 COSM6958005 central nervous system,brain,glioma,ependymoma Grade III-IV c.380+2T>C p.? 13:48342716-48342716 9
20 COSM3662777 central nervous system,brain,glioma,ependymoma Grade III-IV c.2491A>G p.T831A 7:152247943-152247943 9
21 COSM6968456 central nervous system,brain,glioma,ependymoma Grade III-IV c.2105C>A p.A702D 5:180621168-180621168 9
22 COSM6289135 central nervous system,brain,glioma,ependymoma Grade III-IV c.2143G>A p.D715N 19:11010400-11010400 9
23 COSM1578803 central nervous system,brain,glioma,ependymoma Grade III-IV c.1157G>A p.R386H 22:23834152-23834152 9
24 COSM6968459 central nervous system,brain,glioma,ependymoma Grade III-IV c.14765G>A p.G4922E 7:152138845-152138845 9
25 COSM6968455 central nervous system,brain,glioma,ependymoma Grade III-IV c.1458C>A p.H486Q 1:46043739-46043739 9
26 COSM40802 ZW10 central nervous system,brain,glioma,NS c.2140C>T p.P714S 11:113736699-113736699 7
27 COSM40801 ZSWIM4 central nervous system,brain,glioma,NS c.266C>T p.P89L 19:13799832-13799832 7
28 COSM6932117 ZRSR2 central nervous system,brain,glioma,NS c.271G>A p.E91K 23:15803755-15803755 7
29 COSM6948317 ZRSR2 central nervous system,brain,glioma,NS c.340C>T p.Q114* 23:15804138-15804138 7
30 COSM6959574 ZRSR2 central nervous system,brain,glioma,NS c.260G>A p.R87K 23:15803744-15803744 7
31 COSM6932118 ZRSR2 central nervous system,brain,glioma,NS c.961C>T p.P321S 23:15822754-15822754 7
32 COSM6973162 ZRSR2 central nervous system,brain,glioma,oligodendroglioma Grade III c.220G>A p.E74K 23:15803704-15803704 7
33 COSM39611 ZPLD1 central nervous system,brain,glioma,NS c.393A>T p.G131G 3:102456210-102456210 7
34 COSM40237 ZNF687 central nervous system,brain,glioma,NS c.3651C>T p.T1217T 1:151291146-151291146 7
35 COSM39318 ZNF687 central nervous system,brain,glioma,NS c.2044T>A p.C682S 1:151288335-151288335 7
36 COSM39317 ZNF687 central nervous system,brain,glioma,NS c.2043G>C p.Q681H 1:151288334-151288334 7
37 COSM39149 ZNF507 central nervous system,brain,glioma,NS c.1517G>C p.R506T 19:32354347-32354347 7
38 COSM40794 ZNF473 central nervous system,brain,glioma,NS c.42C>T p.D14D 19:50039193-50039193 7
39 COSM39217 ZMYND8 central nervous system,brain,glioma,NS c.2162T>G p.V721G 20:47246130-47246130 7
40 COSM40504 ZMYND8 central nervous system,brain,glioma,NS c.2176G>A p.D726N 20:47246116-47246116 7
41 COSM39507 ZMAT4 central nervous system,brain,glioma,NS c.76G>A p.E26K 8:40825601-40825601 7
42 COSM39445 ZIC1 central nervous system,brain,glioma,NS c.57G>A p.A19A 3:147410169-147410169 7
43 COSM6976869 ZFHX3 central nervous system,brain,glioma,NS c.4279G>A p.A1427T 16:72798403-72798403 7
44 COSM6929045 ZFHX3 central nervous system,brain,glioma,NS c.3607G>T p.E1203* 16:72811961-72811961 7
45 COSM6950242 ZFHX3 central nervous system,brain,glioma,oligodendroglioma Grade III c.8300G>A p.G2767E 16:72794382-72794382 7
46 COSM6959528 ZFHX3 central nervous system,brain,glioma,NS c.145C>T p.P49S 16:72960001-72960001 7
47 COSM5385367 ZFHX3 central nervous system,brain,glioma,NS c.934G>A p.D312N 16:72959212-72959212 7
48 COSM6980194 ZFHX3 central nervous system,brain,glioma,oligodendroglioma Grade III c.6025T>C p.Y2009H 16:72796657-72796657 7
49 COSM5981027 ZFHX3 central nervous system,brain,glioma,NS c.8647A>G p.M2883V 16:72794035-72794035 7
50 COSM3888943 ZFHX3 central nervous system,brain,glioma,NS c.8198G>A p.R2733H 16:72794484-72794484 7

Copy number variations for Glioma from CNVD:

7 (show top 50) (show all 1065)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13321 2 208809197 208828051 Copy number IDH1 Glioma
2 14132 1 10403401 10408000 Deletion Glioma
3 14198 1 105227801 105232100 Deletion Glioma
4 15004 1 111800000 116100000 Deletion Glioma
5 15199 1 113411001 113417300 Deletion BC037540 Glioma
6 15250 1 113839501 113849000 Deletion Glioma
7 15641 1 117679901 117685200 Deletion Glioma
8 15695 1 118394101 118397900 Deletion Glioma
9 19119 1 148648801 148652600 Deletion Glioma
10 19806 1 151480801 151485400 Deletion Glioma
11 20843 1 154791301 154797500 Deletion IQGAP3 Glioma
12 21174 1 157132201 157138600 Deletion Glioma
13 21291 1 157913501 157918300 Deletion Glioma
14 21685 1 160317401 160321200 Deletion Glioma
15 23692 1 173061201 173070300 Deletion Glioma
16 24042 1 174742901 174746800 Deletion Glioma
17 24302 1 178448601 178452400 Deletion Glioma
18 25156 1 185029601 185033600 Deletion Glioma
19 25220 1 185729601 185734900 Deletion Glioma
20 25241 1 185980701 185991100 Deletion Glioma
21 25290 1 186804101 186808700 Deletion Glioma
22 25655 1 192615401 192619700 Deletion Glioma
23 26024 1 195765301 195771800 Deletion Glioma
24 26054 1 196268601 196275300 Deletion Glioma
25 26178 1 197703301 197708700 Deletion Glioma
26 26883 1 20368201 20372100 Deletion PLA2G2C Glioma
27 26979 1 204445801 204451500 Deletion Glioma
28 27209 1 205357001 205361800 Deletion Glioma
29 27636 1 210535701 210541200 Deletion Glioma
30 27909 1 215522601 215526900 Deletion Glioma
31 27938 1 216247201 216257200 Deletion Glioma
32 27948 1 216310301 216315100 Deletion Glioma
33 28054 1 217987801 217992100 Deletion Glioma
34 28169 1 219443901 219451100 Deletion Glioma
35 28238 1 220438701 220448900 Deletion Glioma
36 28860 1 226089101 226092600 Deletion Glioma
37 29433 1 232027401 232031900 Deletion Glioma
38 29707 1 234613701 234620000 Deletion Glioma
39 29744 1 234984301 234988400 Deletion ACTN2 Glioma
40 29950 1 238457901 238463400 Deletion Glioma
41 29974 1 238682401 238685500 Deletion Glioma
42 30033 1 239425501 239429300 Deletion Glioma
43 30273 1 241490101 241494000 Deletion Glioma
44 30527 1 244220301 244224400 Deletion Glioma
45 30564 1 244503701 244507900 Deletion Glioma
46 30805 1 246116501 246126100 Deletion OR2W3 Glioma
47 31058 1 25029301 25036000 Deletion Glioma
48 31536 1 28129101 28135200 Deletion SMPDL3B Glioma
49 31728 1 30200000 32400000 Deletion Glioma
50 33111 1 42513801 42517800 Deletion FOXJ3 Glioma
Sources

Expression for Glioma

About this section
Search GEO for disease gene expression data for Glioma.
Sources

Pathways for Glioma

About this section

Pathways related to Glioma according to KEGG:

37
# Name Kegg Source Accession
1 Glioma hsa05214
2 MicroRNAs in cancer hsa05206

Pathways related to Glioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
MicroRNAs in cancer 37
11.64 MIR15B MIR17 MIR181A2 MIR21 MIR221 MIR222
2
miRNAs involved in DNA damage response 1
11.13 MIR15B MIR221 MIR222
3
Cell Differentiation - Index 1
10.84 MIR146B MIR181A2 MIR221 MIR222
4
LncRNA-mediated mechanisms of therapeutic resistance 1
10.41 HOTAIR MEG3 UCA1
Sources

GO Terms for Glioma

About this section

Cellular components related to Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 micro-ribonucleoprotein complex GO:0035068 9.4 H19 MEG3 MIR146B MIR15B MIR17 MIR181A2

Biological processes related to Glioma according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.93 FOXO1 MIR15B MIR21 MIR221
2 negative regulation of gene expression GO:0010629 9.88 CDKN2B-AS1 MIR17 MIR181A2 MIR21
3 positive regulation of protein kinase B signaling GO:0051897 9.83 MIR21 MIR221 MIR222
4 cellular response to hypoxia GO:0071456 9.79 MALAT1 MIR17 MIR34A
5 negative regulation of angiogenesis GO:0016525 9.71 MIR15B MIR21 MIR222 MIR34A
6 positive regulation of epithelial to mesenchymal transition GO:0010718 9.67 MIR21 MIR221 MIR222
7 positive regulation of erythrocyte differentiation GO:0045648 9.65 MIR221 MIR222
8 chromatin silencing GO:0006342 9.65 CDKN2B-AS1 HOTAIR
9 negative regulation of vascular endothelial cell proliferation GO:1905563 9.65 MIR15B MIR34A
10 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.64 MIR15B MIR222
11 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.64 MIR21 MIR221
12 regulation of reactive oxygen species metabolic process GO:2000377 9.63 FOXO1 MIR21
13 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.62 MIR21 MIR34A
14 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.61 MIR221 MIR222
15 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.61 MIR17 MIR34A
16 negative regulation of sprouting angiogenesis GO:1903671 9.61 MIR17 MIR221 MIR34A
17 positive regulation of endothelial cell differentiation GO:0045603 9.6 MIR181A2 MIR21
18 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.59 MIR17 MIR21
19 positive regulation of connective tissue replacement GO:1905205 9.58 MIR15B MIR34A
20 negative regulation of vascular smooth muscle cell differentiation GO:1905064 9.57 MIR15B MIR221
21 positive regulation of metalloendopeptidase activity GO:1904685 9.56 MIR17 MIR21
22 negative regulation by host of viral genome replication GO:0044828 9.55 MIR221 MIR222
23 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.54 MIR17 MIR21
24 positive regulation of axon regeneration GO:0048680 9.52 MIR221 MIR222
25 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.51 MIR221 MIR222
26 negative regulation of cell adhesion molecule production GO:0060354 9.48 MIR221 MIR222
27 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.46 MIR221 MIR222
28 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.46 MIR17 MIR21 MIR221 MIR222
29 miRNA mediated inhibition of translation GO:0035278 9.43 MIR15B MIR17 MIR181A2 MIR21 MIR221 MIR222
30 gene silencing by miRNA GO:0035195 9.4 H19 MEG3 MIR146B MIR15B MIR17 MIR181A2
31 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.37 MIR221 MIR222
32 positive regulation of Schwann cell migration GO:1900149 9.32 MIR221 MIR222
33 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.26 MIR221 MIR222

Molecular functions related to Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.28 MIR146B MIR15B MIR17 MIR181A2 MIR21 MIR221
Sources

Sources for Glioma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....